Prognostic value of DNA ploidy in 653 Japanese women with node-negative breast cancer

International Journal of Clinical Oncology

Volumn 6, Issue 4, 2001, Pages 177-182

  Tsutsui, S ^a   Ohno, S ^b   Murakami, S ^b   Hachitanda, Y ^b   Oda, S ^b  

^a NATIONAL HOSPITAL ORGANIZATION BEPPU MEDICAL CENTER   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Breast cancer; DNA ploidy; Node negative; Prognosis

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR;

ADULT; AGED; ANEUPLOIDY; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; DNA DETERMINATION; FEMALE; FLOW CYTOMETRY; FROZEN SECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0034789832     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00012103     Document Type: Article

References (34)

1. Ethnic variation in breast cancer survival: A review
2. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, 133 randomized trials involving 31000 recurrences and 24 000 deaths among 75 000 women
3. Prognosis in T2N0M0 stage I breast carcinoma: A 20-year follow-up study
4. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow up
5. DNA ploidy, S-phase, and steroid receptors in more than 127000 breast cancer patients
6. ERBB2 oncogene in human breast cancer and its clinical significance
7. p53 as a prognostic factor in stage I breast cancer
8. A flow cytometric analysis of DNA content in primary and metastaic lesions of esophageal squamous cell carcinoma
9. Prognostic significance of flow cytometric DNA analysis in node-negative breast cancer patients
10. Tumor DNA ploidy as an independent prognostic factor in breast cancer
11. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry
12. The prognostic significance of nuclear DNA content in invasive breast cancer - A study with long-term follow up
13. Flow cytometric DNA ploidy defines patients with poor prognosis in node-negative breast cancer
14. Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity
15. Prognostic significance of proliferative activity and ploidy in node-negative breast cancers
16. The relation of flow cytometry to clinical and biologic characteristics in women with node-negative primary breast cancer
17. Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients
18. Indicators of prognosis in node-negative breast cancer
19. Node-negative breast cancer: Prognostic subgroups defined by tumor size and flow cytometry
20. Prognostic significance of DNA-pliody in a series of 690 primary breast cancer patients
21. Is DNA ploidy an independent prognostic indicator in infiltrative node-negative breast adenocarcinoma?
22. The importance of DNA flow cytometry in node-negative breast cancer
23. DNA flow cytometry and pathologic grading as prognostic guides in axillary lymph node-negative breast cancer
24. Lymph node metastases versus DNA ploidy as prognostic factors for invasive ductal carcinoma of the breast
25. DNA ploidy and Helix pomatia lectin binding as predictors of regional lymph node metastases and prognostic factors in breast cancer
26. Relationship between DNA ploidy and survival in breast cancer
27. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis
28. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer
29. Flow cytometric DNA analysis is useful in detecting multiple genetic alterations in squamous cell carcinoma of the esophagus
30. The relationship of DNA ploidy to chromosomal instability in primary human colorectal cancers
31. Origins and clinical implications of aneuploidy in early bladder cancer
32. Comparison of cell nuclear DNA contents between intraepithelial and invasive components of oesophageal squamous cell carcinoma
33. Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer
34. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes